Core Viewpoint - The company is utilizing idle funds from its non-public stock issuance for cash management to enhance the value of raised funds and increase company earnings while ensuring the normal implementation of investment projects and the safety of raised funds [1][3]. Cash Management Purpose - The cash management aims to better preserve and increase the value of the raised funds, thereby benefiting all shareholders [1]. Cash Management Amount - The company plans to use 100 million yuan (10,000 million) of idle funds from its non-public stock issuance for cash management [1][3]. Fund Source - The funds are sourced from the net proceeds of a non-public stock issuance approved by the China Securities Regulatory Commission, totaling approximately 3.05 billion yuan [1][2]. Investment Project Progress - As of December 31, 2024, the investment projects funded by the non-public stock issuance are as follows: - Expansion of in vitro diagnostic product capacity: Adjusted total investment of 1.43 billion yuan, with cumulative investment of 523.92 million yuan - In vitro diagnostic product R&D center: Adjusted total investment of 833 million yuan, with cumulative investment of 349.66 million yuan - Diagnostic instrument industrial park: Adjusted total investment of 201.89 million yuan, with cumulative investment of 162.18 million yuan [2]. Cash Management Types and Procedures - The cash management products include structured deposits, large certificates of deposit, treasury reverse repos, broker income certificates, and broker wealth management products, all of which are low-risk and have high liquidity [3][5]. Cash Management Duration - The duration of the cash management products will not exceed 12 months [5]. Financial Data Overview - As of March 31, 2025, the company reported total assets of approximately 1.20 billion yuan and total liabilities of approximately 299.82 million yuan, with net assets attributable to shareholders of approximately 887.69 million yuan [7]. Impact of Cash Management - The cash management is expected to improve the efficiency of fund utilization and generate certain investment returns for shareholders, without affecting the normal operation of investment projects [7].
安图生物: 安图生物关于使用闲置募集资金进行现金管理的进展公告